The majority of scientists accept the first offer they receive when transitioning into industry. In some cases that is fine — a few companies genuinely open with their best number. More often, there is room to negotiate, and the scientist who asks calmly and professionally will finish their career substantially better off than the one who didn’t.
This is not about being aggressive or difficult. It is about understanding how hiring in biotech and pharma actually works, knowing what is reasonable to ask for, and having a clear, confident response ready when an offer arrives.
Why Scientists Do Not Negotiate (And Why They Should)
The reasons are predictable. Academia does not teach negotiation. Postdoc salaries are non-negotiable; PI salary decisions are opaque; the culture is to accept what you’re offered and be grateful for funding. When scientists move into industry, they carry that conditioning into a context where it actively costs them money.
The structural reality of biotech hiring is different. Most companies have salary bands for each role, and the first offer is rarely the top of the band. HR and hiring managers expect negotiation. Being the one person in a hiring cycle who doesn’t negotiate does not make you seem more agreeable — it just costs you money over the life of the job and affects the base from which future raises compound.
A 10% increase on a $120,000 offer is $12,000 per year. Over five years at that company, even without raises, that is $60,000 in difference. The downside of asking — in the overwhelming majority of cases — is that the company says no and you accept the original offer. Offers are almost never rescinded for professional counteroffers.
Know Your Market Value Before You Respond
Do not respond to an offer without data. The goal is to understand the realistic range for your role, level, and geography before you say anything. You have several sources:
H-1B salary databases. The U.S. Department of Labor publishes H-1B wage data that companies file when sponsoring foreign workers. Because companies must disclose the actual role title and salary, this is some of the most reliable public compensation data available. levels.fyi/h1b provides a searchable interface. Search for your target company and role title.
LinkedIn Salary. LinkedIn Salary (available to premium subscribers, though some data is visible without) aggregates self-reported data by role, company, and location. It is noisier than H-1B data but covers more roles and companies.
Glassdoor and Levels.fyi. Self-reported data for specific companies. Quality varies widely by company and role. Cross-reference with at least one other source before treating it as accurate.
Talking to people. If you have contacts at the company — from graduate school, conferences, LinkedIn — a direct conversation is the most reliable data you will get. People in industry are generally more open about compensation than academics expect. Asking a peer “what’s a fair range for this role at your company?” is not unusual.
Biotech-specific resources. LifeSciHub and biotech-focused communities on LinkedIn and Reddit (r/biotech, r/labrats) occasionally have compensation threads with industry-specific data. Take community data as a directional signal, not a precise benchmark.
Once you have a range in mind, identify where the offer lands within it. If it’s at or above the 75th percentile for the role in that market, negotiating hard on base salary may be less impactful than focusing on other components. If it’s below median, you have a clear case to make.
What Is Negotiable Beyond Base Salary
Base salary gets the most attention, but it is not the only variable. In biotech and pharma, the following are commonly negotiable:
Signing bonus. Companies can often offer signing bonuses more easily than base salary increases because sign-ons are one-time costs that don’t affect the salary band, future raises, or retirement contributions. If base salary is truly at the band ceiling, asking for a signing bonus is often more productive. A range of $5,000 to $25,000 is common depending on seniority.
Annual bonus target. Many biotech roles come with a target bonus expressed as a percentage of base (often 8–15% for scientist-level roles, higher for more senior positions). Some companies will negotiate whether you start at the minimum or midpoint of the target range for your level.
Equity or RSUs. At publicly traded companies, restricted stock units are often negotiable in terms of grant size, though vesting schedule is usually fixed. At private companies, option grants (strike price, number of options, cliff and vesting schedule) can sometimes be negotiated, particularly for more senior hires.
Start date. This is almost always negotiable and often overlooked. If you have a conference, a visa issue, or simply need time, ask. Companies expect some flexibility here.
Relocation assistance. If you are moving cities or states, ask. Companies often have a relocation package that is not automatically offered until you ask, ranging from a flat stipend to full moving expenses.
PTO and remote work. At some companies, these are genuinely flexible, particularly for senior hires. More variable than compensation, but worth understanding before you accept.
How to Respond to an Offer
When the offer comes, do not respond immediately. The appropriate response in the moment is: “Thank you — this is exciting. Can I have a few days to review the full package?” No company will retract an offer because you asked for time to consider it. Taking 48 to 72 hours to think through the numbers is standard and professional.
When you come back with a counteroffer, keep it simple and positive. You are not negotiating against them — you are working toward a package you can enthusiastically accept. A template that works:
“I’m really excited about this role and the team. Based on my research on compensation for this position in this market, I was hoping we could get to [X] on base salary. Is that something that is possible?”
Keep the tone collaborative and specific. A concrete number is better than a range — ranges anchor to the low end. If base salary is genuinely at the ceiling, you can follow with: “If base is fixed, would a signing bonus be possible to bridge the gap?”
If they come back with a partial increase, you can either accept or ask once more: “That is helpful, thank you. Is there any flexibility to get closer to [Y]?” Most hiring managers can make a second move; almost no one can make a third. After two rounds, you accept or decline.
Common Mistakes
Accepting the same day. This signals that you did not evaluate the offer against market data. Even if you plan to accept, ask for time.
Negotiating via email without talking first. Email is easily misread. A phone call where you sound enthusiastic but measured lands better than a written counter that can read as cold.
Anchoring too low. If you ask for $5,000 more than the offer, you probably receive $2,500. If you ask for $15,000 more (based on actual market data), you might receive $8,000 to $10,000. Research your number and ask for the real market value, not a modest increment.
Negotiating against yourself. Do not say “I know this might not be possible, but…” or “I understand if it’s not feasible.” You undermine your position before you’ve made the ask.
Ignoring the full package. Two offers with the same base salary can differ significantly in total compensation. A company with 15% target bonus, meaningful equity, good health insurance, and full tuition reimbursement is worth more than a higher base with a weak benefits package.
A Note on Timing in Your Career
The negotiation dynamics differ at different career stages.
For a first industry role directly out of a PhD or postdoc, the most common failure is underpricing because you are comparing the offer to your academic salary, not to the market. A PhD-level associate scientist offer in a major biotech hub should typically be in the $95,000 to $130,000 range before bonuses; postdocs transitioning to scientist roles often see $105,000 to $145,000 depending on company size and location. If an offer falls significantly below that range, ask.
For lateral moves from one company to another, you have more leverage. Your current salary establishes a floor, and companies typically need to offer a meaningful increase (often 10–20%) to motivate a move. If the offer does not clear that bar, it is worth saying so: “I’m currently at [X] and a move would need to make financial sense — is there flexibility to get to [Y]?”
For internal promotions, the dynamics are different and typically more constrained by internal band structure. But even here, discussing promotion timing and bonus eligibility is appropriate.
The Bottom Line
Ask. Do it professionally, ground it in data, and stay positive throughout. The worst likely outcome is a polite “the offer is firm” and you accept what you were going to accept anyway. The best outcome is several thousand dollars per year for the rest of your time at that company, compounding forward through every raise.
Scientists are trained to be skeptical and rigorous. Apply the same standards to evaluating a compensation offer as you would to evaluating a paper: check the data, identify what you don’t know, and don’t accept a conclusion you haven’t verified.
For more on navigating the industry transition, see How to Land Your First Industry Job After a PhD.